Oral SMA drug Evrysdi prescribed at tertiary hospitals
By Eo, Yun-Ho | translator Kim, Jung-Ju
23.08.13 18:50:26
가나다라
0
Is in drug pricing negotiations with NHIS... final step to reimb
Attention rises on whether the first oral treatment option for SMA will be born in Korea
According to industry sources, Roche Korea’s SMA treatment Evrysdi (risdiplam) passed the drug committee (DC) reviews at the Big 5 tertiary hospitals in Korea - Samsung Medical Center, Seoul National University Hospital, Seoul, Asan Medical Center, Seoul St.Mary’s Hospital, and Sinchon Severance Hospital – and many other major medical institutions including the Gangnam Severance Hospital, Pusan National University Hospital at Yangsan, and Yongin Severance Hospital.
As Roche is currently in the final negotiation stage with the National Health Insurance Service for Evry
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)